Rheumatoid Arthritis,Osteoarthritis
Conditions
Keywords
Arcoxia
Brief summary
The study is designed to compare the risk of cardiovascular events (heart attacks, strokes) in patients receiving either etoricoxib or diclofenac. It will also compare the gastrointestinal tolerability of the two medicines. The study will be conducted in patients with either rheumatoid or osteo-arthritis.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient has a clinical diagnosis of either Osteoarthritis or Rheumatoid Arthritis and in the opinion of the investigator will require chronic nonsteroidal anti-inflammatory or COX-2 inhibitor therapy for at least 1.5 years
Exclusion criteria
* Concurrent medical or arthritic disease that could confound or interfere with efficacy evaluation. * Concomitant therapy of warfarin, heparin, high-dose aspirin (\>100 mg/day). * Impaired kidney function, clinical gastrointestinal malabsorption, congestive heart failure with symptoms that occur at rest, unstable angina, uncontrolled high blood pressure, active hepatitis/hepatic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Confirmed Thrombotic Cardiovascular Serious Adverse Experiences based on combined data from this trial and MK0663 Protocols 061 & 072 (GI Tolerability in OA Patients and GI Tolerability Study in RA Patients ), respectively. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Confirmed Thrombotic Cardiovascular Serious Adverse Experiences from this trial alone. Gastrointestinal tolerability based on the percentage of patients that discontinue for clinical or laboratory gastrointestinal adverse experiences. | — |